Nuvation Bio (NYSE:NUVB) Earns “Buy” Rating from HC Wainwright

Nuvation Bio (NYSE:NUVB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $21.00 target price on the stock. HC Wainwright‘s price objective indicates a potential upside of 442.78% from the stock’s current price.

Several other analysts have also recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Wednesday, September 16th. B. Riley Financial reissued a “buy” rating on shares of Nuvation Bio in a research report on Friday, August 7th. Cantor Fitzgerald began coverage on Nuvation Bio in a research note on Friday, August 21st. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada decreased their price objective on Nuvation Bio from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.89.

Get Our Latest Report on Nuvation Bio

Nuvation Bio Trading Down 3.0%

Nuvation Bio stock opened at $3.87 on Tuesday. Nuvation Bio has a 52 week low of $3.82 and a 52 week high of $9.75. The company has a debt-to-equity ratio of 1.23, a quick ratio of 7.30 and a current ratio of 7.45. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -9.67 and a beta of 1.73. The company has a 50 day moving average price of $5.07 and a 200 day moving average price of $5.33.

Nuvation Bio (NYSE:NUVB – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%. The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $34.39 million. Research analysts forecast that Nuvation Bio will post -0.37 EPS for the current year.

Insiders Place Their Bets

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $7.09, for a total value of $709,000.00. Following the transaction, the insider owned 100,000 shares in the company, valued at approximately $709,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 30.11% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in shares of Nuvation Bio during the 1st quarter valued at $2,399,000. Bank of New York Mellon Corp acquired a new position in shares of Nuvation Bio in the second quarter worth $3,804,000. NewEdge Advisors LLC raised its holdings in shares of Nuvation Bio by 19.5% during the second quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company’s stock worth $6,996,000 after acquiring an additional 200,621 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Nuvation Bio during the second quarter worth $625,000. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Nuvation Bio by 75.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company’s stock worth $6,175,000 after acquiring an additional 619,725 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

Featured Articles

Analyst Recommendations for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.